ReviewHepatology international2016
New therapeutic targets in alcoholic hepatitis.
Review in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis.Langenbeck's archives of surgery · 2018Pooled it
- U-shaped associations between body mass index and serum liver enzyme levels.Scientific reports · 2025Article
- Hepatic β-arrestins: potential roles in liver health and disease.Molecular biology reports · 2023Review
- CD73 Attenuates Alcohol-Induced Liver Injury and Inflammation via Blocking TLR4/MyD88/NF-κB Signaling Pathway.Journal of inflammation research · 2022Article
- NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.Theranostics · 2020Article
- Cilostazol protects hepatocytes against alcohol-induced apoptosis via activation of AMPK pathway.PloS one · 2019Article
- Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics.Nutrients · 2018Review
- Triiodothyronine alleviates alcoholic liver disease injury through the negative regulation of the NLRP3 signaling pathway.Experimental and therapeutic medicine · 2018Article
- Controversies in clinical trials for alcoholic hepatitis.Journal of hepatology · 2018Review
- β-Arrestin 2 Promotes Hepatocyte Apoptosis by Inhibiting Akt Pathway in Alcoholic Liver Disease.Frontiers in pharmacology · 2018Article
- Gut-liver axis and sterile signals in the development of alcoholic liver disease.Alcohol and alcoholism (Oxford, Oxfordshire) · 2017Review
- Emerging concepts in alcoholic hepatitis.World journal of hepatology · 2017Review
- Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.Gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alcoholic liver disease (ALD) is a leading cause of liver-related morbidity and mortality worldwide. ALD encompasses a spectrum of disorders including asymptomatic steatosis, steatohepatitis, fibrosis, cirrhosis and its related complications, and the acute-on-chronic state of alcoholic hepatitis. While multidisciplinary efforts continue to be aimed at curbing progression of this spectrum of disorders, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of ALD. AH is characterized by an abrupt development of jaundice and complications related to liver insufficiency and portal hypertension in patients with heavy alcohol intake. The mortality of patients with severe AH is very high (20-50 % at 3 months). The current therapeutic regimens are limited. The development of new therapies requires translational studies in human samples and suitable animal models that reproduce clinical and histological features of human AH. This review article summarizes the clinical syndrome, pre-clinical translational tools, and pathogenesis of AH at a molecular and cellular level, with the aim of identifying new targets of potential therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.